Brief: Nicox Sees Top-Line Results Of NCX 4251 Blepharitis Trial In Sept.
02/07/2021 07:00
July 2 (Reuters) - Nicox SA NCOX.PA :
* NICOX ANNOUNCES LAST PATIENT COMPLETED NCX 4251
MISSISSIPPI
PHASE 2B BLEPHARITIS TRIAL
* TOP-LINE RESULTS ARE EXPECTED TO BE ANNOUNCED IN SEPTEMBER
2021
* PHASE 2B MISSISSIPPI TRIAL IS DESIGNED TO FURTHER EXPLORE
NCX
4251 PRODUCT PROFILE FOLLOWING ENCOURAGING RESULTS OF PHASE 2
DANUBE TRIAL
* ANNOUNCED THAT LAST PATIENT IN NCX 4251 MISSISSIPPI PHASE
2B
BLEPHARITIS CLINICAL TRIAL HAS NOW COMPLETED TWO-WEEK TREATMENT
PHASE AS WELL AS REQUIRED TWO-WEEK FOLLOW UP PERIOD
* WE WILL ANNOUNCE NEXT STEPS IN DEVELOPMENT OF NCX 4251
FOLLOWING
AN END-OF-PHASE 2 MEETING WITH FDA
* NICOX AND OCUMENSION THERAPEUTICS HAVE ENTERED INTO AN
EXCLUSIVE
LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NCX
4251 FOR BLEPHARITIS IN CHINESE MARKET
Source text for Eikon: ID:nGNXb9GG7g
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))